Latest Breaking News On - Yonsei university college - Page 1 : vimarsana.com

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Byoung chol choYonsei university college of medicineYonsei cancer centerDivision of medical oncologyMedical oncologyYonsei university college

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4.

Soult ukpyolsiSouth koreaBaden wübergUnited statesHye ryun kimMary beth sandinAndreas harstrickAlexander fudukidisArtiva alloUniversity of texas md anderson cancer centerProfessor at yonsei university college of medicineChief medicalChief executive officerYonsei university collegeCancer center

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Region flamandeSoult ukpyolsiSouth koreaUnited statesRepublic of koreaByoung chul choHenar heviaCraig tendlerAmerican lung associationSlate developmentJanssen cilag internationalAmerican society of clinical oncologyEuropean medicines agency seeking approvalJanssen cilag international nv incCommittee for medicinal products human useNational cancer institute

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 - Affimed (NASDAQ:AFMD)

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control

Soult ukpyolsiSouth koreaUnited statesBaden wübergMary beth sandinArtiva alloHye ryun kimAndreas harstrickAlexander fudukidisUniversity of texas md anderson cancer centerAmerican society of clinical oncologyProfessor at yonsei university college of medicineAmerican societyClinical oncologyChief medicalChief executive officer

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Soult ukpyolsiSouth koreaUnited statesBaden wübergAndreas harstrickAlexander fudukidisArtiva alloHye ryun kimMary beth sandinProfessor at yonsei university college of medicineAmerican society of clinical oncologyUniversity of texas md anderson cancer centerAnnounces positive early efficacyProgression free survival resultsType non small cell lung cancerAnnual meeting